• Policy
• PVA is a variable in the negotiation of α-GPC recovery
• by Lee, Hye-Kyung Jun 8, 2021 06:01am

• Company
• Pros and cons of the spin-offs and sales of Big Pharmas
• by Eo, Yun-Ho Jun 8, 2021 06:01am

• Policy
• Pipeltro/Delstrigo will be reimbursed if the amount offered
• by Lee, Hye-Kyung Jun 8, 2021 06:00am

• Company
• HPV vaccine market expands 55% midst COVID-19
• by An, Kyung-Jin Jun 7, 2021 06:06am

• Policy
• Ultomiris can be reimbursed with prior approval
• by Lee, Hye-Kyung Jun 7, 2021 06:06am

• Policy
• SK Bio regains license for 'SKYPneumo'
• by Lee, Tak-Sun Jun 7, 2021 06:06am

• Policy
• Botulinum Toxin is poorly managed
• by Lee, Jeong-Hwan Jun 7, 2021 06:05am

• Policy
• Improvements to exempted calculation of psoriasis are urged
• by Kim, Jung-Ju Jun 7, 2021 06:05am

• Policy
• NA prepares bill to prevent 'price cut lawsuit' gimmicks
• by Lee, Jeong-Hwan Jun 4, 2021 06:06am

• Company
• Sales in the herpes zoster market have halved in 2 years
• by An, Kyung-Jin Jun 4, 2021 06:06am